Portage Biotech

89 articles with Portage Biotech

• Portage Biotech Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity

  4/25/2022

  Portage Biotech Inc. (NASDAQ: PRTG), today announced that it has entered a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the U.S. National Institutes of Health, and Stimunity, S.A.S, an affiliate of Portage with experience in the preclinical development of stimulator of interferon genes (STING) agonists for cancer immunotherapy and infectious diseases.

• 

  AACR: Advances in Immune System Stimulation and Cell Transplants Favor Oncology

  4/15/2022

  BioSpace looked at some of the efforts to improve the host system’s immune response, as well as others to improve allogeneic or autologous cell transplants.

• Portage Biotech Highlights Promising Data Presented on STING-Activating Therapy, PORT-5 (STI-001) at AACR 2022 Annual Meeting

  4/13/2022

  Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today highlighted data being presented in collaboration with Stimunity during the American Association for Cancer Research (AACR) 2022 Annual Meeting.

• Portage Biotech Provides Update on Clinical-Stage and Development Programs

  3/31/2022

  Portage Biotech Inc., a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, provided an update on its clinical development programs and announced its development goals for the remainder of 2022.

• Portage Biotech Announces Presentation of PORT-5 (STI-001) Late-Breaking Data at AACR 2022 Annual Meeting

  3/9/2022

  Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), today announced data from a collaboration on a STING-activating therapy, PORT-5 (STI-001) will be presented at the American Association for Cancer Research (AACR) 2022 Annual Meeting.

• Portage Biotech Announces Financial Results and Provides Business Update for Third Quarter of 2022 Fiscal Year

  2/24/2022

  Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced financial results for the quarter ended December 31, 2021 (the “third quarter”).

• Portage Biotech Announces New Appointments to its Management Team and Board of Directors

  2/15/2022

  Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced new appointments to its management team and Board of Directors.

• 

  Biopharma Executive Perspectives on 2022

  1/10/2022

  BioSpace sat down with 12 executives who shared their thoughts on the coming year and decade.

• Portage Biotech Announces Participation in January 2022 Investor Conferences

  1/5/2022

  Portage Biotech Inc., a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, announced that the Company will participate in three investor conferences during the month of January.

• Portage Biotech Announces Financial Results and Provides Business Update for Second Quarter of 2022 Fiscal Year

  11/23/2021

  Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), today announced financial results for the quarter ended September 30, 2021 (the “second quarter of Fiscal 2022”).

• Portage Biotech to Present at the Piper Sandler 33rd Annual Healthcare Conference

  11/22/2021

  Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), today announced that Chief Executive Officer, Dr. Ian Walters, will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference being held on November 29-December 2, 2021.

• Portage Biotech Highlights Promising Efficacy and Survival Data Presented on Intensity Therapeutics’ INT230-6 (PORT-1) at November Scientific Conferences

  11/15/2021

  Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today highlighted data being presented by Intensity Therapeutics during the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting and the Connective Tissue Oncology Society (CTOS) Annual Meeting

• Portage Biotech Hosting Key Opinion Leader Webinar on How iNKT Agonists Could Improve Immuno-Oncology TreatmentThursday, November 18th @ 10amET

  11/10/2021

  Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), today announced that it will host a key opinion leader (KOL) webinar on the role iNKT cells play in anticancer immune response and how iNKT targeting can be leveraged to expand the immuno-oncology landscape, Thursday, November 18, 2021, at 10a.m. Eastern Time.

• Portage Biotech Announces Participation in September 2021 Investor Conferences

  9/10/2021

  Portage Biotech Inc. today announced that as part of its commitment to investor outreach, management will be participating in the following investor conferences in September 2021. H.C. Wainwright 23rd Annual Global Investor Conference Date: September 13, 2021

• Portage Biotech Announces Results for First Quarter of 2022 Fiscal Year

  8/30/2021

  Portage Biotech Inc. today announced financial results for the quarter ended June 30, 2021.

• 

  Clinical Catch-Up: August 2-6

  8/9/2021

  It was a busy week for clinical trial announcements. Take a look.

• Portage Biotech Highlights First Patient Dosed in IMP-MEL Study of PORT-2 for the Treatment of Melanoma and Non-Small Cell Lung Cancer (NSCLC)

  8/5/2021

  Portage Biotech Inc. announced that the first patient has been dosed in the Oxford-led IMP-MEL study, a Phase 1/2, open-label, dose-escalation and randomized expansion clinical trial assessing the safety, tolerability and efficacy of PORT-2, a liposome formulation of the invariant natural killer T-cell agonist IMM60 developed for the treatment of solid tumors.

• Portage Biotech Announces Results for Fiscal Year Ended March 31, 2021

  7/28/2021

  Portage Biotech Inc. a clinical-stage immuno-oncology company focused on the development of therapies and treatments targeting cancer treatment resistance, announced financial results for the fiscal year ended March 31, 2021.

• Portage Announces Results of Annual Meeting; Private Placement Update; Corporate Update

  6/26/2020

   Portage Biotech Inc. (CSE: PBT.U) (OTC Markets: PTGEF) ("Portage" or the "Company") is very pleased to announce the results of its annual meeting of shareholders (the "Meeting") held on June 25, 2020 . Over 70% of all issued and outstanding common shares of the Company were represented at the Meeting. In line

• Portage Raises More Than US$6.7 Million Through Non-Brokered Private Placement; Temporary Symbol Change on OTC Markets

  6/16/2020

  TORONTO, June 16, 2020 /PRNewswire/ - Portage Biotech Inc. is very pleased to announce that, further to its news release dated May 25, 2020, it has closed a non-brokered private placement for gross proceeds of US$6,788,600 through the issuance of 678,860 common shares at a price of US$10.00 per Common Share.